The Latest Breaking News from PFE

Pfizer Inc (PFE), currently trading at a discount, is charting a path to enduring expansion via strategic acquisitions and the introduction of novel products. Despite this drive, recent financial results lack significant optimism. Given this scenario, should investors invest in PFE? Let’s look at its financial metrics to gauge its…

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

US stock markets delivered stellar returns in the first half of the year and the Nasdaq 100 had its best first-half performance ever. However, Pfizer, whose COVID-19 vaccine made the company a household name recently fell to a 52-week low. Why is Pfizer stock going down and should you buy…

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

Rivian’s strong sales results drove the unusual options activity in Friday trading. For those who aren’t enamored with the electric vehicle manufacturer’s business, there are, pardon the pun, other options.

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

The pharma sector is poised to witness significant growth due to the widespread adoption of generic medicines and emerging technologies. Therefore, fundamentally strong pharma stocks Pfizer (PFE), Sanofi (SNY), and Spero Therapeutics (SPRO) might be solid buys. Read on.

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…